

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended): A bispecific binding molecule, whereby said molecule comprises at least two domains,
- (a) wherein one of said at least two domains specifically binds to/interacts with the human CD3 complex, wherein said domain comprises an amino acid sequence of an antibody derived light chain having the amino acid sequence of SEQ ID NO.: 10 or is encoded by a nucleic acid sequence of SEQ ID NO.: 9; and ~~, wherein said amino acid sequence is~~
- (i) ~~an amino acid sequence of SEQ ID NO: 2;~~
- (ii) ~~an amino acid sequence encoded by a nucleic acid sequence corresponding to SEQ ID NO: 1;~~
- (iii) ~~an amino acid sequence encoded by a nucleotide sequence hybridizing with the complementary strand of a nucleic acid sequence as defined in (ii) under stringent conditions; and~~
- (iv) ~~an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence of any one of (ii) and (iii) with the proviso that amino acid sequences according to (i) to (iv) comprise amino acid substitutions in the CDR regions of the light chain in positions L24, L54 and L96 according to the Kabat system; and~~
- (b) wherein a second domain is or contains at least one further antigen-interaction-site and/or at least one further effector domain.

2. (Canceled)

3. (Canceled)

4. (Previously Presented): The bispecific binding molecule according to claim 1, wherein the domain which binds to/interacts with the human CD3 complex is a scFv.

5. (Canceled)

6. (Previously Presented): The bispecific binding molecule according to claim 1, wherein the domain which binds to/interacts with the human CD3 complex comprises or consists of the amino acid sequence as depicted in SEQ ID NO.: 14 or encoded by a nucleic acid sequence of SEQ ID NO: 13.

7. (Previously Presented): The bispecific binding molecule according to claim 1, wherein said second domain is at least one further antigen-interaction-site specific for one or more cell surface molecule(s).

8. (Previously Presented): The bispecific binding molecule according to claim 7, wherein said one or more cell surface molecule(s) is/are a tumor specific molecule(s).

9. (Previously Presented): The bispecific binding molecule according to claim 7, wherein said second domain is a further scFv.

10. (Previously Presented): The bispecific binding molecule according to claim 7, wherein said second domain specifically binds to/interacts with an antigen selected from the group consisting of EpCAM, CCR5, CD19, HER-2, HER-3, HER-4, EGFR, PSMA, CEA, MUC-1 (mucin), MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC7, bhCG, Lewis-Y, CD20, CD33, CD30, ganglioside GD3, 9-O-Acetyl-GD3, GM2,

Globo H, fucosyl GM1, Poly SA, GD2, Carboanhydrase IX (MN/CA IX), CD44v6, Sonic Hedgehog (Shh), Wue-1, Plasma Cell Antigen, (membrane-bound) IgE, Melanoma Chondroitin Sulfate Proteoglycan (MCSP), CCR8, TNF-alpha precursor, STEAP, mesothelin, A33 Antigen, Prostate Stem Cell Antigen (PSCA), Ly-6 desmoglein 4, E-cadherin neoepitope, Fetal Acetylcholine Receptor, CD25, CA19-9 marker, CA-125 marker and Muellierian Inhibitory Substance (MIS) Receptor type II, sTn (sialylated Tn antigen; TAG-72), FAP (fibroblast activation antigen), endosialin, EGFRvIII, L6, SAS, CD63, TF-antigen, Cora antigen, CD7, CD22, Ig $\alpha$ , Ig $\beta$ , gp100, MT-MMPs, F19-antigen and CO-29.

**11. (Currently Amended):** The bispecific binding molecule according to claim 10, wherein said second domain comprises an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence corresponding to SEQ ID NO.: 16 or 18;
- (b) an amino acid sequence encoded by a nucleic acid sequence corresponding to SEQ ID NO.: 15 or 17; **and**
- (c) ~~an amino acid sequence encoded by a nucleic acid sequence hybridizing with the complementary strand of a nucleic acid sequence as defined in (b) under stringent hybridization conditions; and~~
- (d) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence of any one of (b) ~~and (e)~~.

**12. (Currently Amended):** The bispecific binding molecule according to claim 11, wherein said molecule comprises an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence corresponding to SEQ ID NO.: 20

(b) an amino acid sequence encoded by a nucleic acid sequence corresponding to SEQ ID NO.: 21; **and**

(c) ~~an amino acid sequence encoded by a nucleic acid sequence hybridizing with the complementary strand of a nucleic acid sequence as defined in (b) under stringent hybridization conditions; and~~

(d) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence of any one of (b) ~~and (c)~~.

**13. (Currently Amended):** The bispecific binding molecule according to claim 10, wherein said second domain comprises an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence corresponding to SEQ ID NO.: 22, 24, 26, 28, 30, 32;

(b) an amino acid sequence encoded by a nucleic acid sequence corresponding to SEQ ID NO.: 21, 23, 25, 27, 29, 31; **and**

(c) ~~an amino acid sequence encoded by a nucleic acid sequence hybridizing with the complementary strand of a nucleic acid sequence as defined in (b) under stringent hybridization conditions; and~~

(d) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence of any one of (b) and (c).

**14. (Currently Amended):** The bispecific binding molecule according to claim 13, wherein said molecule comprises an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence corresponding to SEQ ID NO.: 34, 36

(b) an amino acid sequence encoded by a nucleic acid sequence corresponding to SEQ ID NO.: 33, 35; **and**

(c) ~~an amino acid sequence encoded by a nucleic acid sequence hybridizing with the complementary strand of a nucleic acid sequence as defined in (b) under stringent hybridization conditions; and~~

(d) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence of any one of (b) and (e).

**15. (Previously Presented):** The bispecific binding molecule according to claim 7, wherein said at least one further antigen-interaction-site is humanized.

**16. (Previously Presented):** A nucleic acid sequence encoding a bispecific binding molecule according to claim 1.

**17. (Currently Amended):** The nucleic acid molecule of claim 16 comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding the mature form of a protein comprising the amino acid sequence selected from the group of SEQ ID NOs: 20, 34, 36;

(b) a nucleotide sequence comprising or consisting of a DNA sequence selected from the group of SEQ ID NOs: 19, 33, 35; **and**

(c) ~~a nucleotide sequence hybridizing with the complementary strand of a nucleotide sequence as defined in (b) under stringent hybridization conditions;~~

(d) a nucleotide sequence encoding a protein **having an amino acid sequence at least 95% identical to the amino acid sequence encoded by the nucleotide sequence of (a) or (b); and** ~~derived from the protein encoded by a nucleotide sequence of (a)~~

~~or (b) by way of substitution, deletion and/or addition of one or several amino acids of the amino acid sequence encoded by the nucleotide sequence of (a) or (b);~~

~~(e) — a nucleotide sequence encoding a protein having an amino acid sequence at least 60 % identical to the amino acid sequence encoded by the nucleotide sequence of (a) or (b); and~~

~~(f)~~**(d)** a nucleotide sequence which is degenerate as a result of the genetic code to a nucleotide sequence of any one of (a) to **(c)** ~~(e)~~.

**18. (Previously Presented):** A vector comprising a nucleic acid sequence according to claim 16.

**19. (Previously Presented):** The vector of claim 18, which further comprises a regulatory sequence operably linked to said nucleic acid sequence.

**20. (Previously Presented):** The vector of claim 18, wherein the vector is an expression vector.

**21. (Previously Presented):** A host transformed or transfected with a vector according to claim 18.

**22. (Previously Presented):** A process for the production of a bispecific binding molecule according to claim 1, said process comprising culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1 under conditions allowing the expression of the bispecific binding molecule and recovering the produced bispecific binding molecule from the culture.

**23. (Previously Presented):** A composition comprising a bispecific binding molecule according to claim 1, a nucleic acid molecule encoding the bispecific

binding molecule of claim 1, a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1 or a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1 and, optionally, a proteinaceous compound capable of providing an activation signal for immune effector cells.

**24. (Original):** The composition of claim 23 which is a pharmaceutical composition further comprising suitable formulations of carrier, stabilizers and/or excipients.

**25. (Original):** The composition of claim 23 which is a diagnostic composition further comprising means and methods for detection of proliferative diseases, tumorous diseases, inflammatory diseases, immunological disorders, autoimmune diseases, infectious diseases, viral diseases, allergic reactions, parasitic reactions, graft-versus-host diseases or host-versus-graft diseases.

**26. (Canceled)**

**27. (Currently Amended):** A method for the ~~prevention~~, treatment or amelioration of a proliferative disease, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, viral disease, allergic reactions, parasitic reactions, graft-versus-host diseases or host-versus-graft diseases in a subject in the need thereof, said method comprising the step of administering an effective amount of the bispecific binding molecule according to claim 1, a nucleic acid molecule encoding the bispecific binding molecule of claim 1, a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1 or a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1.

**28. (Original):** The method of claim 27, wherein said subject is a human.

**29. (Previously Presented):** The method of claim 27 further comprising the administration of a proteinaceous compound capable of providing an activation signal for immune effector cells.

**30. (Previously Presented):** The method of claim 27, further comprising the administration of a proteinaceous compound capable of providing an activation signal for immune effector cells, wherein said proteinaceous compound is administered simultaneously or non-simultaneously with said bispecific binding molecule, said nucleic acid molecule, said vector, or said host.

**31. (Previously Presented):** A kit comprising the bispecific binding molecule according to claim 1, a nucleic acid molecule comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1, a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1 or a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the bispecific binding molecule of claim 1.